TBPH — Theravance Biopharma Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapSuper Stock

Annual cashflow statement for Theravance Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-199	-92.8	-55.2	-56.4	106
Depreciation
Deferred Taxes
Non-Cash Items	25.2	-140	31.3	30.4	22.1
Discontinued Operations
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	-39.6	42.4	-8.34	20.4	120
Change in Accounts Receivable
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Cash from Operating Activities	-208	-187	-27	-11.5	239
Capital Expenditures	-3.41	-0.572	-2.49	-0.332	-0.042
Purchase of Fixed Assets
Other Investing Cash Flow Items	128	1,155	-30.2	12.6	-105
Sale of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Change in Net Investments
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	124	1,154	-32.7	12.3	-105
Financing Cash Flow Items	3.47	5.08	0.618	0.508	—
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	91.9	-759	-199	-2.5	-3.25
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	8.5	208	-259	-1.75	130